Evgen Pharma, now operating under the name TheraCryf plc, is focused on developing innovative therapeutics for oncology and behavioral brain disorders. The company's lead clinical asset, SFX-01, is a patented sulforaphane-based medicine that has shown promising results in preclinical models for glioblastoma, a severe form of brain cancer. The data indicates potential for tumor shrinkage and extended survival times in patients. Additionally, TheraCryf is advancing other drug candidates, including an orexin 1 receptor antagonist aimed at treating addiction and anxiety disorders, and an atypical dopamine transporter inhibitor that may alleviate central fatigue and address narcolepsy.

TheraCryf's strategy emphasizes generating compelling data to attract partnerships with larger pharmaceutical companies, which can facilitate the transition of their proprietary drug candidates through extensive clinical trials and into commercial markets. The company leverages its expertise in drug development and commercialization, supported by a seasoned leadership team and a Scientific Advisory Board, to navigate the complexities of bringing these innovative therapeutics to fruition.

United Kingdom

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Evgen Pharma

Company Details